<rst>
<header>
	<relations>
			<rel name="elaboration" type="rst"/>
			<rel name="means" type="rst"/>
			<rel name="circumstance" type="rst"/>
			<rel name="condition" type="rst"/>
			<rel name="purpose" type="rst"/>
			<rel name="restatement" type="rst"/>
			<rel name="preparation" type="rst"/>
			<rel name="sequence" type="multinuc"/>
			<rel name="same_unit" type="multinuc"/>
			<rel name="joint" type="multinuc"/>
		</relations>
</header>
<body>
<segment id="1" parent="1001" relname="preparation">1.</segment>
<segment id="2" parent="1002" relname="preparation">Introduction</segment>
<segment id="3" parent="1003" relname="span">Cholesterol is predominantly synthesized de novo in the liver with lesser amounts</segment>
<segment id="4" parent="3" relname="elaboration">obtained from the diet .</segment>
<segment id="5" parent="1005" relname="span">Dietary intake , de novo synthesis , metabolism and excretion , combine</segment>
<segment id="6" parent="1006" relname="span">to balance circulating cholesterol levels</segment>
<segment id="7" parent="1007" relname="span">ensuring extra-hepatic tissues are sufficiently equipped</segment>
<segment id="8" parent="7" relname="purpose">to produce a range of metabolites including steroid hormones , bile acids and seco-steroids .</segment>
<segment id="9" parent="1011" relname="span">Side-chain hydroxycholesterols</segment>
<segment id="10" parent="9" relname="elaboration">( scOHCs )</segment>
<segment id="11" parent="1010" relname="same_unit">are typically formed through hydroxylation of cholesterol by specialized members of the Cytochrome P450 family ,</segment>
<segment id="12" parent="1013" relname="span">which bind and activate the Liver X Receptor-alpha</segment>
<segment id="13" parent="12" relname="elaboration">( LXRA ; gene name NR1H3 )</segment>
<segment id="14" parent="1015" relname="span">and beta</segment>
<segment id="15" parent="14" relname="elaboration">( LXRB ; gene name NR1H2 )</segment>
<segment id="16" parent="1014" relname="same_unit">transcription factors .</segment>
<segment id="17" parent="1002" relname="joint">LXR target genes are typically involved in cholesterol and fatty acid metabolism .</segment>
<segment id="18" parent="1018" relname="span">In normal tissue , expression of LXRA is inducible in the liver , intestine , macrophages and adipocytes ,</segment>
<segment id="19" parent="18" relname="circumstance">whilst expression of LXRB is more ubiquitous .</segment>
<segment id="20" parent="1021" relname="circumstance">As well as differences in expression of LXRA and LXRB , local concentrations of the scOHCs differ considerably between tissues , and relative to each other ,</segment>
<segment id="21" parent="1021" relname="joint">sometimes by as much as 1000-fold</segment>
<segment id="22" parent="1021" relname="joint">and variance can also depend on disease status .</segment>
<segment id="23" parent="1024" relname="span">Furthermore , the different scOHCs have varying capacities</segment>
<segment id="24" parent="23" relname="purpose">to activate LXR-mediated transcription ,</segment>
<segment id="25" parent="1023" relname="same_unit">imposing an element of selective modulation onto signalling .</segment>
<segment id="26" parent="1026" relname="span">26-OHC</segment>
<segment id="27" parent="1027" relname="span">( commonly referred to as 27-OHC )</segment>
<segment id="28" parent="27" relname="purpose">for example is the most abundant scOHC ,</segment>
<segment id="29" parent="1002" relname="joint">but is a relatively weak LXR agonist .</segment>
<segment id="30" parent="1002" relname="joint">Moreover , there is little difference in scOHC concentrations between breast cancer subtypes .</segment>
<segment id="31" parent="1033" relname="span">Transcriptional activity of the LXRs , like the other members of the Nuclear Receptor</segment>
<segment id="32" parent="31" relname="elaboration">( NR ) superfamily ,</segment>
<segment id="33" parent="1032" relname="same_unit">is not just regulated by ligand bioavailability ;</segment>
<segment id="34" parent="1002" relname="joint">chromatin environment , cross-talk and competition for response element binding with other NRs , as well as cell- and tissue-type dependent expression of cofactors are also key mediators .</segment>
<segment id="35" parent="1002" relname="joint">For example , the expression of corepressors such as NCOR1 and NCOR2/SMRT determine how several cancers respond to nutritive ligands .</segment>
<segment id="36" parent="1002" relname="joint">LXRA has a 100-fold higher binding affinity than LXRB for the corepressors NCOR1 and NCOR2</segment>
<segment id="37" parent="1038" relname="span">and deregulation of these corepressors allows prostate and bladder cancer cells to evade cancer suppressive signals of Vitamin D</segment>
<segment id="38" parent="1039" relname="span">( through repression of Vitamin D Receptor</segment>
<segment id="39" parent="38" relname="restatement">( VDR ) )</segment>
<segment id="40" parent="1041" relname="span">and omega-3 fatty acids</segment>
<segment id="41" parent="1042" relname="span">( through repression of peroxisome proliferator-activated receptors</segment>
<segment id="42" parent="41" relname="restatement">( PPARs ) )</segment>
<segment id="43" parent="1041" relname="means">by impairing sensitivity to ligand .</segment>
<segment id="44" parent="1044" relname="span">Simply measuring scOHC concentrations</segment>
<segment id="45" parent="1045" relname="span">does not sufficiently determine their contributions to LXR signalling ;</segment>
<segment id="46" parent="45" relname="elaboration">concentration and activation potential should be assessed in combination .</segment>
<segment id="47" parent="1047" relname="span">In cancer , the function of the scOHC-LXR signalling axis appears site specific</segment>
<segment id="48" parent="47" relname="circumstance">as both tumour suppressive and promoting roles have been described .</segment>
<segment id="49" parent="1050" relname="joint">For example , scOHC-LXR signalling impairs invasion and angiogenesis in melanoma</segment>
<segment id="50" parent="1050" relname="joint">and is anti-proliferative in lung cancer in vivo ,</segment>
<segment id="51" parent="1051" relname="span">as it is in almost every cancer cell line</segment>
<segment id="52" parent="51" relname="elaboration">studied in vitro .</segment>
<segment id="53" parent="1054" relname="span">In Oestrogen Receptor</segment>
<segment id="54" parent="1055" relname="span">( ER)-positive Breast Cancer</segment>
<segment id="55" parent="54" relname="restatement">( BCa )</segment>
<segment id="56" parent="1053" relname="same_unit">however 26-OHC promotes growth in vivo via ER-alpha .</segment>
<segment id="57" parent="1057" relname="joint">In ER-negative BCa 26-OHC drives the epithelial-to-mesenchymal transition</segment>
<segment id="58" parent="1057" relname="joint">and promotes colonization of metastatic sites in through mobilization of γδ-T cells .</segment>
<segment id="59" parent="1059" relname="joint">Furthermore , concentrations of several scOHCs are altered in BCa relative to normal tissue ,</segment>
<segment id="60" parent="1061" relname="span">and 25-OHC is elevated in the circulation of BCa patients</segment>
<segment id="61" parent="60" relname="elaboration">who have relapsed</segment>
<segment id="62" parent="1060" relname="same_unit">compared to those with primary disease .</segment>
<segment id="63" parent="1063" relname="sequence">We recently evaluated LXR ligand bio-availability in a small BCa cohort</segment>
<segment id="64" parent="1063" relname="sequence">and found large inter tumoural heterogeneity in oxysterol content , but no difference in ligand concentrations between tumour subtypes .</segment>
<segment id="65" parent="1066" relname="condition">Systematic evaluation of scOHC bioavailability and activation potential ,</segment>
<segment id="66" parent="1066" relname="span">coupled with analysis of NR cofactor expression between BCa subtypes</segment>
<segment id="67" parent="66" relname="elaboration">has not been performed previously .</segment>
<segment id="68" parent="1068" relname="span">Given the prognostic and therapeutic value</segment>
<segment id="69" parent="68" relname="elaboration">of stratifying BCa by hormone receptor status ,</segment>
<segment id="70" parent="1070" relname="span">further delineation of the pathways</segment>
<segment id="71" parent="70" relname="elaboration">that are altered between these subtypes , such as scOHC-LXR signalling ,</segment>
<segment id="72" parent="1071" relname="joint">may help advance understanding about the emerging roles of cholesterol metabolism in cancer</segment>
<segment id="73" parent="1071" relname="joint">and improve outcomes for patients .</segment>
<group id="1000" type="span" />
<group id="1001" type="span" parent="1000" relname="span"/>
<group id="1002" type="multinuc" parent="1001" relname="span"/>
<group id="1003" type="span" parent="1002" relname="joint"/>
<group id="1005" type="span" parent="1002" relname="joint"/>
<group id="1006" type="span" parent="5" relname="purpose"/>
<group id="1007" type="span" parent="6" relname="elaboration"/>
<group id="1009" type="span" parent="1002" relname="joint"/>
<group id="1010" type="multinuc" parent="1009" relname="span"/>
<group id="1011" type="span" parent="1010" relname="same_unit"/>
<group id="1012" type="multinuc" parent="1010" relname="elaboration"/>
<group id="1013" type="span" parent="1012" relname="same_unit"/>
<group id="1014" type="multinuc" parent="1012" relname="same_unit"/>
<group id="1015" type="span" parent="1014" relname="same_unit"/>
<group id="1018" type="span" parent="1002" relname="joint"/>
<group id="1020" type="span" parent="1002" relname="joint"/>
<group id="1021" type="multinuc" parent="1020" relname="span"/>
<group id="1023" type="multinuc" parent="1002" relname="joint"/>
<group id="1024" type="span" parent="1023" relname="same_unit"/>
<group id="1026" type="span" parent="1002" relname="joint"/>
<group id="1027" type="span" parent="26" relname="elaboration"/>
<group id="1032" type="multinuc" parent="1002" relname="joint"/>
<group id="1033" type="span" parent="1032" relname="same_unit"/>
<group id="1037" type="multinuc" parent="1002" relname="joint"/>
<group id="1038" type="span" parent="1037" relname="same_unit"/>
<group id="1039" type="span" parent="37" relname="elaboration"/>
<group id="1040" type="span" parent="1037" relname="same_unit"/>
<group id="1041" type="span" parent="1040" relname="span"/>
<group id="1042" type="span" parent="40" relname="elaboration"/>
<group id="1044" type="span" parent="1002" relname="joint"/>
<group id="1045" type="span" parent="44" relname="elaboration"/>
<group id="1046" type="span" parent="1002" relname="joint"/>
<group id="1047" type="span" parent="1046" relname="span"/>
<group id="1048" type="multinuc" parent="1047" relname="elaboration"/>
<group id="1049" type="multinuc" parent="1048" relname="joint"/>
<group id="1050" type="multinuc" parent="1049" relname="same_unit"/>
<group id="1051" type="span" parent="1049" relname="same_unit"/>
<group id="1052" type="multinuc" parent="1048" relname="joint"/>
<group id="1053" type="multinuc" parent="1052" relname="joint"/>
<group id="1054" type="span" parent="1053" relname="same_unit"/>
<group id="1055" type="span" parent="53" relname="elaboration"/>
<group id="1056" type="multinuc" parent="1052" relname="joint"/>
<group id="1057" type="multinuc" parent="1056" relname="joint"/>
<group id="1058" type="multinuc" parent="1056" relname="joint"/>
<group id="1059" type="multinuc" parent="1058" relname="sequence"/>
<group id="1060" type="multinuc" parent="1059" relname="joint"/>
<group id="1061" type="span" parent="1060" relname="same_unit"/>
<group id="1062" type="multinuc" parent="1058" relname="sequence"/>
<group id="1063" type="multinuc" parent="1062" relname="joint"/>
<group id="1064" type="multinuc" parent="1062" relname="joint"/>
<group id="1065" type="span" parent="1064" relname="joint"/>
<group id="1066" type="span" parent="1065" relname="span"/>
<group id="1067" type="span" parent="1064" relname="joint"/>
<group id="1068" type="span" parent="1069" relname="circumstance"/>
<group id="1069" type="multinuc" parent="1067" relname="span"/>
<group id="1070" type="span" parent="1069" relname="same_unit"/>
<group id="1071" type="multinuc" parent="1069" relname="same_unit"/>
	</body>
</rst>
